ABT

Abbott Laboratories
D

ABT

Arincen83/100B
115.550
USD
6.14
(5.61%)
Post Trading·115.230USD-0.320(-0.28%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Abbott Laboratories executives and insider trading

Robert Ford bought 18,800 shares for 2.01M USD and sold 398,832 for 46.20M USD on the open market over the last twelve months.

Over the last twelve months Abbott Laboratories's insiders sold 410,494 shares for 47.54M USD in 11 sales on the open market, and bought 43,000 shares in 6 purchases.

Insiders over the last twelve months

Insider sales
11
Shares sold
410,494
Value sold
47.54M USD
Insider purchases
6

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
46.85M USD
173.64K USD
6 months
46.85M USD
4.40M USD
1 year
47.54M USD
4.40M USD
2 years
123.18M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Robert Ford CEOExecutive Chairman & CEO52398,83246.20M USD18,80025 Aug 2026—
Daniel J Starks Director———20,000——
Louis H. Morrone EXECUTIVE VICE PRESIDENT—6,994774.73K USD—11 Aug 2026—
Eric Shroff Senior Vice President—2,295284.99K USD—2 Mar 2026—
Philip Boudreau Chief Financial Officer & Executive Vice President of Finance53——2,200——
John G Stratton Director———2,000——
Daniel Gesua Sive Salvadori Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products47885102.29K USD—2 Mar 2026—
Mary K Moreland EXECUTIVE VICE PRESIDENT—61370.85K USD—2 Mar 2026—
John A. Jr. Mccoy VICE PRESIDENT AND CONTROLLER—61270.57K USD—2 Sept 2026—
Elizabeth Cushman Executive Vice President, General Counsel & Secretary5626330.40K USD—2 Mar 2026—

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
2 Sept 2026John A. Jr. MccoySale27109.542.96K USD24,549Form 4
25 Aug 2026Robert FordSale218,535115.5725.26M USD486,758Form 4
25 Aug 2026Robert FordSale180,297116.1920.95M USD306,461Form 4
11 Aug 2026Louis H. MorroneSale5,850109.83642.51K USD70,724Form 4
7 May 2026John G StrattonPurchase2,00086.82173.64K USD23,319Form 4
27 Apr 2026Daniel J StarksPurchase10,00092.65926.54K USD6,751,103Form 4
23 Apr 2026Philip BoudreauPurchase2,20091.50201.30K USD2,200Form 4
2 Mar 2026Eric ShroffSale709115.5881.95K USD39,164Form 4
2 Mar 2026Daniel Gesua Sive SalvadoriSale885115.58102.29K USD146,377Form 4
2 Mar 2026Louis H. MorroneSale1,144115.58132.22K USD76,843Form 4
2 Mar 2026Mary K MorelandSale613115.5870.85K USD104,291Form 4
2 Mar 2026John A. Jr. MccoySale585115.5867.61K USD24,628Form 4
2 Mar 2026Elizabeth CushmanSale263115.5830.40K USD38,573Form 4
4 Feb 2026Daniel J StarksPurchase5,033108.33545.24K USD6,738,817Form 4
4 Feb 2026Daniel J StarksPurchase4,967109.14542.09K USD6,733,784Form 4

Common questions about Abbott Laboratories's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.